Cargando…

Correction: Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy

Detalles Bibliográficos
Autores principales:	Gritt, Giuseppe, Gianatt, Andrea, Petronzeii, Fiorella, De Santis, Rita, Pavoni, Chiara, Rossi, Riccardo Lorenzo, Cattaneo, Laura, Spagnoli, Luigi Giusto, Ferrar, Silvia, Ross, Andrea, Barbu, Anna Maria, Rambald, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908322/ https://www.ncbi.nlm.nih.gov/pubmed/29683132 http://dx.doi.org/10.18632/oncotarget.25064

Ejemplares similares

Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy
por: Gritti, Giuseppe, et al.
Publicado: (2018)

Radioimmunotherapy of B-Cell Non-Hodgkin’s Lymphoma
por: Bodet-Milin, Caroline, et al.
Publicado: (2013)

Radioimmunotherapy with tositumomab and iodine-131 tositumomab for non-Hodgkin’s lymphoma
por: Andemariam, Biree, et al.
Publicado: (2007)

Radioimmunotherapy of Non-Hodgkin’s Lymphoma: From the ‘Magic Bullets’ to ‘Radioactive Magic Bullets’
por: Chamarthy, Murthy R., et al.
Publicado: (2011)

Radioimmunotherapy in Non-Hodgkin’s Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar
por: Sachpekidis, Christos, et al.
Publicado: (2019)

Pretargeted Molecular Imaging and Radioimmunotherapy
por: Goldenberg, David M., et al.
Publicado: (2012)

Theragnostic Aspects and Radioimmunotherapy in Pediatric Tumors
por: Cimini, Andrea, et al.
Publicado: (2020)

Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin’s lymphoma
por: Burdick, Michael J, et al.
Publicado: (2009)

Standard Operating Procedure for In-house Preparation of (131)I-rituximab for Radioimmunotherapy of Non-Hodgkin's Lymphoma
por: Pickford, Matthew D., et al.
Publicado: (2012)

Development of DOTA-Rituximab to be Labeled with (90)Y for Radioimmunotherapy of B-cell Non-Hodgkin Lymphoma
por: Johari doha, Fariba, et al.
Publicado: (2017)

Radioimmunotherapy-based conditioning regimen prior to autologous stem cell transplantation in non-Hodgkin lymphoma
por: Eskian, Mahsa, et al.
Publicado: (2018)

Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma
por: Herrera, Alex F., et al.
Publicado: (2021)

Radioimmunotherapy for solid tumors: spotlight on Glypican-1 as a radioimmunotherapy target
por: Sabanathan, Dhanusha, et al.
Publicado: (2021)

Standard Operating Procedure for Prospective Individualised Dosimetry for ([131])I-rituximab Radioimmunotherapy of Non-Hodgkin's Lymphoma
por: Calais, Phillipe J., et al.
Publicado: (2012)

Immunostimulatory effects of radioimmunotherapy
por: Constanzo, Julie, et al.
Publicado: (2022)

The distribution of tenascin-X is distinct and often reciprocal to that of tenascin-C
Publicado: (1994)

Radioimmunotherapy: a brief overview
por: Ng, DCE
Publicado: (2006)

Is radioimmunotherapy a 'magic bullet'?
por: Kim, Sung-Hyun
Publicado: (2012)

Improvement of Radioimmunotherapy Using Pretargeting
por: Frampas, Eric, et al.
Publicado: (2013)

Trial Watch: Anticancer radioimmunotherapy
por: Vacchelli, Erika, et al.
Publicado: (2013)

Tenascin turns on the EGFR
por: Jegalian, Karin
Publicado: (2001)

The evolution of tenascins and fibronectin
por: Adams, Josephine C, et al.
Publicado: (2015)

Invasion of Melanoma in Double Knockout Mice Lacking Tenascin‐X and Tenascin‐C
por: Matsumoto, Ken‐ichi, et al.
Publicado: (2002)

Imaging of Early Response to Predict Prognosis in the First-Line Management of Follicular Non-Hodgkin Lymphoma with Iodine-131-Rituximab Radioimmunotherapy
por: Kesavan, Murali, et al.
Publicado: (2017)

Combination Radioimmunotherapy Strategies for Solid Tumors
por: Zaheer, Javeria, et al.
Publicado: (2019)

Editorial: Radioimmunotherapy—Translational Opportunities and Challenges
por: Gaipl, Udo S., et al.
Publicado: (2020)

Dynamics of an Antitumour Model with Pulsed Radioimmunotherapy
por: Wang, Gang, et al.
Publicado: (2022)

Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with (90)Y and (111)In for domestic radioimmunotherapy and radioscintigraphy of Non-Hodgkin’s Lymphoma
por: Gholipour, Nazila, et al.
Publicado: (2014)

Anti-CD37 radioimmunotherapy with (177)Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin’s lymphoma in vitro
por: Malenge, Marion M., et al.
Publicado: (2022)

Induction of tenascin in healing wounds
Publicado: (1988)

Tenascin Supports Lymphocyte Rolling
por: Clark, Rachael A., et al.
Publicado: (1997)

Advances in tenascin-C biology
por: Midwood, Kim S., et al.
Publicado: (2011)

Tenascin-C and integrins in cancer
por: Yoshida, Toshimichi, et al.
Publicado: (2015)

Transcriptional regulation of tenascin genes
por: Chiovaro, Francesca, et al.
Publicado: (2015)

Immunosuppression via Tenascin-C
por: Bellone, Matteo, et al.
Publicado: (2015)

Tenascin-X and the pick of destiny
por: Short, Ben
Publicado: (2014)

Tenascin C in Lung Diseases
por: Donovan, Chantal, et al.
Publicado: (2023)

Amino acid sequence of mouse tenascin and differential expression of two tenascin isoforms during embryogenesis
Publicado: (1991)

Early Days of Tenascin-R Research: Two Approaches Discovered and Shed Light on Tenascin-R
por: Rathjen, Fritz G., et al.
Publicado: (2021)

Heterogeneity of intratumoral (111)In-ibritumomab tiuxetan and (18)F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin’s lymphoma
por: Hanaoka, Kohei, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_d8fgq51pmt00v5936l4io65d56